Form 4: ALX Oncology Director Acquires Stock Options

Rekha Hemrajani, a director at ALX Oncology Holdings Inc., was granted stock options for 40,400 shares at an exercise price of $1.65.

Summary

• Rekha Hemrajani, a director of ALX Oncology Holdings Inc., has been granted stock options to purchase 40,400 shares of common stock.
• The exercise price for these options is $1.65 per share.
• The options were granted on January 21, 2025, and will vest in 12 equal monthly installments starting February 21, 2025.
• The options expire on January 20, 2035.
• A power of attorney was also filed, authorizing certain individuals to act on Hemrajani's behalf for SEC filings related to her transactions in ALX Oncology securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock options to a director, which is generally viewed as a positive sign of alignment between management and shareholders. There is no indication of any negative sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 12 months is typical for such grants.
• The exercise price is usually set at or above the market price at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of director alignment with company performance.
• The director is incentivized to increase the company's value to benefit from the stock options.

Key Dates

Keywords

stock options, director, ALX Oncology, insider trading, SEC Form 4, equity compensation, corporate governance